Kiora Q2 FY26 net loss narrows to $2.1 million
Reuters2026/08/07 11:06- Kiora Pharmaceuticals posted a Q2 net loss of USD 2.08 million, narrowing from USD 2.15 million a year earlier; loss per share improved to USD 0.34 from USD 0.54.
- R&D expense fell to USD 2.08 million from USD 2.59 million; collaboration credits declined to USD 1.34 million from USD 1.69 million.
- Cash and short-term investments rose to about USD 16.8 million at June 30 from USD 13.9 million at March 31, extending expected runway into late 2028.
- Private placement secured for up to USD 24 million in gross proceeds, including USD 5 million upfront; remaining proceeds tied to milestone-based warrant exercises.
- ABACUS-2 advanced into a 100 µg dose cohort with topline data expected in Q3 2027; KLARITY higher-dose enrollment continues with initial data expected late 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Titanium and refractory metal powder manufacturer Amaero (AMRO.US) submits IPO application, plans to raise $50 million
Amaero (AMRO.US), a producer specializing in titanium and refractory metal powders for defense and aerospace 3D printing, has recently filed a registration statement with the U.S. Securities and Exchange Commission, planning to raise up to $50 million through an initial public offering.
Industrivarden reports 431,899,108 shares outstanding, 232,757,574 voting rights
Devyser appoints Torben Thölix as chief commercial officer
Hoist Finance issued shares, voting rights rise to 87,852,320
Crypto prices
More
